Bristol-Myers, DTMI establish strategic research partnership
Initially, DTMI will work with BMY on the clinical development of BMS-986202, an orally available lysophosphatidic acid 1 receptor antagonist under investigation to treat idiopathic pulmonary fibrosis. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.